Recent advances in treatment of drug resistant Tuberculosis

23/7/2010
CASE FINDING

• Patients at risk of DR-TB should be screened for drug resistance
• In pts with HIV, when possible, DST should be performed at the start of anti-TB therapy to avoid mortality due to unrecognized DR-TB
• For the initial screening of DR-TB, rapid DST methods should be used whenever possible
• Patients at increased risk of XDR-TB should be screened for resistance with DST of isoniazid, rifampicin, the second-line injectable agents and a fluoroquinolone.
- Design treatment regimens based on the hierarchy.
- Use at least 4 drugs with either certain, or almost certain, effectiveness.
- DST should generally be used to guide therapy; however do not depend on DST in individual regimen design for ethambutol, pyrazinamide, and Group 4 and 5 drugs.
- Treat for 18 months past culture conversion.
- Use adjunctive measures -surgery and nutritional social support.
- Treat adverse effects immediately and adequately.
• In Seven-year DOTS-Plus pilot experience in India: Of the 126 patients enrolled, 61% were cured, 19% died, 18% defaulted and 3% failed treatment.


• MDR-TB case fatality in NON HIV Pts is 26%(16-58%).
• XDR-TB has been reported on 6 continents in at least 37 countries, constituting up to 10% of all MDR-TB strains.
• Much more difficult to treat than MDR-TB and is extremely difficult to treat in HIV-positive patients.
• Reports of HIV positive patients being promptly diagnosed with XDR-TB and placed on an adequate regimen are non-existent to date
• Cohorts of HIV-negative XDR patients have been shown to have cure rates that exceed 50%
Fluoroquinolones

• Against DNA gyrase
• second-line therapy for the treatment of MDR-TB.
• comparable with the bactericidal activity of rifampicin


• Moxi>> Oflox> cipro
• In a Phase 2 controlled trial in which patients were randomized to receive 8 weeks of therapy with either standard treatment or the combination of H,R,Z and with either ofloxacin, moxifloxacin, or gatifloxacin, the rates of elimination of M tuberculosis from serial sputum cultures were more rapid in the gatifloxacin- and moxifloxacin-containing regimens than in the ofloxacin-containing or the standard regimen.

• When given in combination with R and Z, moxifloxacin has been reported to reduce treatment time by up to 2 months compared with an H,R and Z combination.


• In a Phase 2a EBA study conducted in Tanzania, moxifloxacin (400 mg daily) was as efficacious as isoniazid (300 mg daily) and more efficacious than rifampicin (600 mg daily).

• Phase 2b trial conducted in Brazil, the moxifloxacin-containing regimen achieved a higher rate of culture conversion at 2 months compared with the standard ethambutol-containing regimen.

• Two Phase 3 randomized controlled trials are presently underway which investigate the safety and efficacy of 4-month treatment regimens including those that replace ethambutol or isoniazid with gatifloxacin or moxifloxacin.

RIFAPENTINE

• selective inhibitors of bacterial RNA polymerase, an essential enzyme for DNA transcription.
• Close analogue of rifampicin; not active against rifampicin resistant mutants.
• Extended terminal half life; can be used in intermittent therapy.
• Poor inducer of CYP450
• But underrepresented in clinical trials of HIV pts
Rifapentine +Mxfl +Z daily or thrice-weekly therapy allowed shortening of treatment from 6 to 3 months or less in mice. 


Daily regimens rifapentine +H+ Z produced a stable cure in mice after 10 weeks of therapy, whereas mice receiving standard RHZ regimen relapsed after 12 weeks of treatment.

Diarylquinoline: TMC-207

• Most advanced compound presently in clinical development.
• Target of TMC-207 is ATP synthase, the powerhouse of the tubercle bacillus.
• Potent against both sensitive & resistant MTB strains.
• Potent activity against M avium, M marinum, M fortuitum, M abscessus, and M smegmatis
• Killing is time dependent but not concentration dependent.
• Potent late bactericidal activity.
• Long tissue half life & high tissue penetration
• Linear pharmacokinetics
• Absorption ↑es with food.
• CyP450 3A4 → interaction with R.
• TMC-207/HZ and TMC-207/RZ combinations cleared the infections in the lungs of all mice after 2 months of therapy.

• Phase 2b placebo-controlled, double-blind, randomized trial preliminary results of the 2-month treatment Phase showed that the combination of the background MDR-TB treatment with TMC-207 provided a higher sputum culture conversion (48%) in patients than the background regimen combined with placebo (9%).

• Compared with the standard combination RHZ, TMC-207 at 5, 10, and 15 mg/kg exhibited better bactericidal activity than the 3-drug combination after 6 weeks of therapy.

Lenaerts AJ et al. Chemother 2007;51(9):3338–45
Nitroimidazoles

- Bioreduction of the nitroimidazole pharmacophore
- Reactive chemical species generated
- Through this bioreduction process is presumed
PA-824

• highly specific with potent activity only against bacillus Calmette-Guerin and M tuberculosis among mycobacterial species tested
• without significant activity against a broad range of gram-positive and gram-negative bacteria (with the exception of Helicobacter pylori and some anaerobes).
• has activity against nonreplicating bacilli, indicating its potential for activity against persisting organisms and shortening duration of treatment
• Nonmutagenic ; excellent tissue penetration
• Orally bioavailable → OD or less frequent dosing
• promising bactericidal activity in mice during the initial intensive Phase of therapy, similar to that of the equipotent dose of INH in humans.

• potent activity during the continuation Phase of therapy in mice, during which it targeted bacilli that had persisted through an initial 2-month intensive Phase of treatment with RHZ.


• Phase 1 trial demonstrated clinically significant bactericidal activity for this drug over a 14-day dosing period when administered orally at 200 to 1200 mg per day.

OPC-67683

- No cross resistance with any first line drugs
- Nonmutagenic
- No P450 drug interactions
- In a mouse model of established infection, the efficacy of OPC-67683 is superior to that of currently used TB drugs.
OPC-67683

- human equipotent dose (to rifampicin) 0.625 mg/kg.
- The combination of OPC-67683+ R+Z → quicker eradication of viable TB bacilli in the mouse lung in comparison with the standard regimen consisting of RHZE.

Ethylendediamine: SQ109

- derivative of ethambutol
- different mode of action from that of ethambutol, and is believed to have synergistic interactions with both INH & R.
- In a mouse model of established infection, substituting SQ109 for ethambutol in the standard regimen demonstrated an improved efficacy.
- A Phase 1 single-dose, dose-escalation study has been completed and a Phase 1 multiple-dose study has been planned.
Oxazolidinones: Linezolid and PNU-100480

- Broad spectrum coverage
- Inhibiting protein synthesis through binding to the 70S ribosomal initiation complex
- Linezolid – used in MDR TB
- ? Unclear role
- S/E- peripheral & optic neuropathy.
- PNU-100480 is close analogue of linezolid.
- Slightly better in vitro activity against M tuberculosis than linezolid.
Oxazolidinones: PNU-100480

• incorporation of PNU-100480 dramatically improved the bactericidal activity of regimens containing current first-line TB drugs and moxifloxacin.

• A regimen combining PNU-100480, moxifloxacin, and Z, which contains neither INH nor R, was more active than the RHZ combination.


• May have the potential to significantly shorten the duration of therapy for both drug-susceptible and drug-resistant TB
Preclinical Discovery Pipeline

• There are about 43 compounds and projects in the global pipeline.
• 34 are in preclinical and discovery stage, including 6 compounds in preclinical development, 8 projects in lead optimization, 6 projects in lead identification, and 14 projects in screening stage
ROLE OF IMMUNOTHERAPY

• The nature of the immune response to TB infection determines whether protective immunity or active disease will be the result.

• Protective immunity is comprised of bacteriostatic and bacteriocidal components.

• Although a bacteriostatic response may transiently protect the host from an invasive pathogen, it does so at the cost of creating dormancy, a source of recurrent infection that can be difficult to eradicate.

• The challenge for immunotherapy is to convert a predominantly bacteriostatic immune response into a bacteriocidal response, or, alternatively, to modify the bacteriostatic response so that it no longer interferes with chemotherapy.
• Optimal bacteriocidal immunity is probably achieved by a combination of the classic type 1 IFN-γ–mediated response plus Cytotoxic-T Lymphocytes.

• ↑ proportion of antigen-specific IL-4– producing T cells, and skewed toward a Th2- type cellular response → increased immunopathology rather than protection
• The aim of immunotherapy is to “realign” or improve the immune response by either promoting protective Th1 immunity or blocking harmful immune (Th2) responses.
• Boosting Th1 responses may induce systemic release of Th1-associated cytokines, resulting in necrosis of TB lesions (Koch phenomenon).
• A better approach may be to optimize the balance between the Th1/Th2 immune response by downregulating the Th2 response
HIGH DOSE IVIg

- high-dose IVIg given in mouse model of TB showed marked therapeutic effect whether administered early or during infection.
- Excellent safety
HE2000 (16a-BROMOEPIANDROSTERONE)

• HE2000 is a modified form of DHEA that cannot go into the sex steroid pathways.

• HE2000 was therapeutic in a mouse model of pulmonary TB, even when given late in the infection, without any chemotherapy. The molecule also showed synergy with antibacterial drugs, leading to accelerated bacillary clearance.
Studies of HE2000 in HIV Pts

• well tolerated and safe in HIV.
• significant decrease in viral load (P<.01).
• reduce the incidence of TB coinfection by 42.2% (P<.05) in a cohort of antiretroviral therapy-naive HIV-infected subjects with advanced HIV disease.

Multidose heat-killed M vaccae

- preparation of an environmental saprophyte.
- inhibit Th2 responses and driving a Th1 response that results in activation of cytotoxic T cells that kill M tuberculosis-infected macrophages.
• In China, multiple injections of M vaccae have been given to patients with recurrent or drug-resistant TB. Significant improvements in sputum conversion rates were claimed.


• Commercially available and licensed as a therapy for TB in China, and a recent meta-analysis of 11 trials of multidose M vaccae undertaken in China concluded that it is effective as an adjunctive treatment in MDR-TB.
DARDAR study

- 5 doses of M vaccae were given to more than 2000 Tanzanians infected with HIV, which resulted in a significant decrease in definite TB in the M vaccae recipients \((P = .027)\).
  most patients were already TB-infected, even if their disease was latent.


- Need for a randomised, blinded trial.
Neutralizing antibodies to IL-4, leading to reduced IL-4 and TGF-β

• ↓IL-4 → ↓TGF-β → ↓TB

• TGF-β blocker → ↓TGF-β → ↑inflammation

• modest decrease in TGF-β caused by blocking IL-4 might be a part of the therapeutic effect.

• Pascolizumab (M Ab to IL-4) → likely to be effective in patients with high IL-4.
DNA vaccine encoding a mycobacterial protein (HSP65)

- major target of the immune response to mycobacteria, profound immunoregulatory properties.
- HSP65 DNA vaccine is effective alone and enhances cytotoxic T cells, while inhibiting the IL-4 response.
- Synergy with antibacterials (Mflx)
- ? S/E→immunopathology in lung lesions in guinea pigs
DNA VACCINE

- DNA vaccine encoding 3 other antigens of MTB: Ag85B, MPT-64, and MPT-83. Used together with antibacterial drugs, this vaccine significantly reduced CFU 3 to 5 months after treatment of infected mice (P<.001).

Hu D H et al Gene Ther 2008;15(9):652–9
DZHERELO

- Plant extract
- Used in Ukraine
- Striking claims when used as adjunct immunotherapy against MDRTB & XDR TB.
- Need for randomised trials.

SCV-07 SciCLone

- Gamma glutamyl-tryptophan
- Immunostimulatory with unknown actions
RUTI

• liposome preparation of M tuberculosis cell wall skeleton.
• RUTI accelerates bacterial clearance when given late in T/t as an adjunct to conventional chemotherapy.


• Phase 1 study
IMMUNOSUPPRESSIVE

• Current AB kill rapidly growing, not nonreplicating bacilli ➔ dormant altered biosynthetic pathway

• Immune system modulation may render dormant bacilli more susceptible to drugs

• S/E ➔ opportunistic infections disease flare up
ROLE OF TNF α

• TNF α is essential for granuloma
• ↓TNFα → ↓granuloma → bacilli in open active state & more susceptible to AB
• Thalidomide → partially block TNFα but not T cells → immunomodulatory & anti immunomodulatory effects
• ↑↑mortality in TBM in HIV uninfected children
• Teratogenic; peripheral neuropathy
THALIDOMIDE ANALOGS

- selective cytokine inhibitory drugs (SelCiDs), has been shown to act via inhibition of PDE4.
- TNF-α PDE4 inhibitor (thalidomide analog)CC3052 cotreatment of infected mice with CC-3052 and INH resulted in improved bacilli killing & clearance.
- T/t with only CC-3052 alone was associated with control of M tuberculosis growth in the lungs during infection similar to that seen in the untreated control mice indicating that the drug is not genuinely immunosuppressive.
anti-TNF-α monoclonal antibody
TN3-19.12

- highly immune suppressive
- ↑↑morbidity & mortality
- Didn’t enhance the efficacy of INH.
Etanercept (soluble TNF-α receptor)

- Adjunctive treatment with etanercept, together with conventional TB chemotherapy, can accelerate the microbiologic response and improve outcome in patients with HIV/TB coinfection.
- Adjunctive etanercept treatment resulted in a trend toward increased CD4+ T cell counts, but there was no effect on plasma HIV RNA levels.

HIGH DOSE PREDNISOLONE

• Phase 2 trial → 187 HIV-infected TB patients (CD4 counts > 200 cells/mm³) were treated with either prednisolone (at 2.75 mg/kg/d) or placebo during the first month of standard TB chemotherapy. Sputum culture conversion rates after 1 month of treatment were 62% & 37% in subjects treated with prednisolone versus placebo, respectively (P < .001), and is the greatest effect on sputum culture conversion observed in any trial of adjunctive therapy in TB, whether chemotherapy or immunotherapy.

• Minor side effects

• Two other prospective clinical trials of adjunctive corticosteroids administered at much lower doses in TB patients have shown acceleration of sputum culture conversion providing further support for the hypothesis of an association between release of immune pressure and improved antibiotic-mediated bacillary clearance.


• Future - ? Inhaled delivery of steroids
**Recombinant Human IFN-γ**

- 5 small trials of aerosolized, s/c or i/m rh IFN-γ or α among patients with multi- or drug-resistant TB.
- Minimal to moderate benefit that was not sustained

**IL-12**

- †es IFN γresponse in MTB stimulated human peripheral mononuclear cells & alveolar macrophages.
- Therapeutic efficacy shown in murine model of PTB
rh IL-2

- promotes T cell proliferation, differentiation, and activation, and is essential for cellular immune function and granuloma formation.
- In 1997, a small, unblinded study in MDR-TB patients of 2 lowdose IL-2 regimens (daily or in 5-day “pulses”) found that the daily regimen appeared to decrease sputum AFB counts.
rh IL-2

- A randomized, double-blind, placebo-controlled trial of the effect of IL-2 on sputum culture conversion was conducted in 110 HIV-uninfected drug-susceptible Ugandan TB cases. Contrary to expectations, the study found reduced clearance of viable M tuberculosis sputum counts and delayed sputum culture conversion in the IL-2 arm. These results suggest that IL-2 may only be beneficial when given adjunctively with MDR-TB drug regimens.

Johnson JL Am J Respir Crit Care Med 2003;168(2):185–91
rh- GMCSF

- ↓replication of MTB
- Only 1 small (n 531) randomized controlled trial of adjunctive rh-GMCSF in patients with newly diagnosed HIV uninfected PTB in Brazil was shown to be safe and well tolerated and showed a trend towards faster sputum conversion.
- BCG-derived GM-CSF resulted in tenfold increased protection against disseminated TB compared with standard BCG alone.
TIME TO RETHINK??

WHO GUIDELINES

- Pt can be emperically started on Cat IV
- T/t can be standardised/individualised.
- BD dose
- Change in T/t if mono/poly resistance
- DST at start of T/t in HIV with PTB

RNTCP-DOTS PLUS

- Only if DST is positive
- Cat IV in R resistance
- T/t is standardised
- 6 (9) Km Ofx (Lvx) Eto Cs Z E / 18 Ofx (Lvx) Eto Cs E
- OD dose of PAS, Eth, Cs
- No change in T/t if mono/poly resistance
SUMMARY

• Potential to cure
• Potential to shorten
• Too early
• Prevention is cure